Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda(®)) to submit evidence of its clinical and cost effectiveness for the treatment of patients with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Sabine E., Fayter, Debra, Ramaekers, Bram L. T., Petersohn, Svenja, Riemsma, Rob, Armstrong, Nigel, Pouwels, Xavier, Witlox, Willem, Noake, Caro, Worthy, Gillian, Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713293/
https://www.ncbi.nlm.nih.gov/pubmed/30895564
http://dx.doi.org/10.1007/s40273-019-00792-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713293/
https://www.ncbi.nlm.nih.gov/pubmed/30895564
http://dx.doi.org/10.1007/s40273-019-00792-7

Ejemplares similares